返回 
加入收藏
贝伐珠单抗联合化疗用于卵巢癌患者的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 贝伐珠单抗联合化疗用于卵巢癌患者的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察贝伐珠单抗联合化疗用于卵巢癌患者的临床疗效及安全性。方法：52例卵巢癌患者按随机数字表法分为对照组22例和观察组30例。对照组患者根据病情选择紫杉醇、卡铂、草酸铂、多柔比星等化疗药物；观察组患者在对照组基础上加用贝伐珠单抗7.5 mg/kg加入250 ml 0.9％氯化钠注射液，化疗开始前1 h ivgtt，首次可行地塞米松10 mg静脉冲入预处理。3周为1个周期，两组患者均治疗4～8个周期。观察两组患者临床疗效、生存时间、生存质量及毒副反应情况。结果：观察组患者临床总有效率为83.3％， 显著高于对照组的54.5％，差异有统计学意义（P＜0.05）；观察组患者生存时间为（34.0±2.4）个月，显著高于对照组的（24.0±3.0）个月，差异有统计学意义（P＜0.05）；观察组患者生存质量评分为（114.5±2.1）分，显著高于对照组的（103.2±2.1）分，差异有统计学意义（P＜0.05）。两组患者毒副反应发生率比较，差异无统计学意义（P＞0.05）。结论：贝伐珠单抗联合化疗用于卵巢癌患者疗效显著，可明显延长患者生存时间、提高生存质量，且安全性较高。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. METHODS： 52 patients with ovarian cancer were randomly divided into control group （22 cases） and observation group （30 cases）. Control group was given paclitaxel， carboplatin， oxaliplatin， doxorubicin and other routine chemotherapy drugs according to disease condition； observation group was additionally given bevacizumab 7.5 mg/kg added into 250 ml 0.9％ Sodium chloride injection， 1 h before chemotherapy， ivgtt， on the basis of control group， and given dexamethasone 10 mg intravenous impulse for pretreatment firstly. A treatment course lasted for 3 weeks， and both groups were given 4-8 courses of treatment. Short-term efficacy， survival time， survival quality and toxic reaction were observed in 2 groups. RESULTS： Short-term total effective rate of observation group was 83.3％， which was significantly higher than 54.5％ of control group， with statistical significance （P＜0.05）； survival time of observation group was （34.0±2.4） months， which was significantly higher than （24.0±3.0） months of control group， with statistical significance （P＜0.05）； survival quality score of observation group was （114.5±2.1）， which was significantly higher than （103.2±2.1） of control group， with statistical significances （P＜0.05）. There was no statistical significance in the incidence of toxic reaction between 2 groups （P＞0.05）. CONCLUSIONS： Bevacizumab combined with chemotherapy shows significant short-term efficacy in the treatment of ovarian cancer， prolongs survival time of patients significantly， and improves survival quality with good safety. |
| 期刊： | 2016年第27卷第11期 |
| 作者： | 熊煜，彭奕华 |
| AUTHORS： | XIONG Yu，PENG Yihua |
| 关键字： | 贝伐珠单抗；卵巢癌；化疗 |
| KEYWORDS： | Bevacizumab； Ovarian cancer； Chemotherapy |
| 阅读数： | 713 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
